- call +1-201-465-4211
- email sales@mrinsights.biz
Obesity is a public health problem. Obesity is a genetic and chronic metabolic disease involving accumulation of excessive or abnormal fat in the body. It contributes to risk of chronic conditions such as cancer, hypertension, cardiovascular diseases, diabetics, obstructive sleep apnea, ventilatory failure, renal failure and asthma. According to a World Health Organization (WHO) report published in 2014, around 3.4 million adults in the world die each year due to obesity related issues. Increasing prevalence of obesity among children and adults is posing a threat and developing nations. Effective intervention strategies such as increased physical activity, behavioral and dietary changes are commonly used to control and prevent obesity. Obesity has a major impact on population longevity and health related expense.
Scope of the Report:
This report focuses on the Anti-Obesity Prescription in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
There is increased use of anti-obesity prescription due to increasing obesity endemic. Sedentary lifestyle and junk food habits, increasing healthcare expenditure and rise in aging population are some of the key factors driving the growth for global anti-obesity prescription market. In addition, increasing healthcare awareness is also fuelling the growth of the global anti-obesity prescription market. However, side effects of anti-obesity drugs, high drug development cost and strict regulatory framework are some of the major factors restraining the growth for the global anti-obesity prescription market.
The worldwide market for Anti-Obesity Prescription is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
Zydus Cadila
Akrimax Pharmaceuticals
Zealand Pharma
Arrowhead Research
Arena Pharmaceuticals
Compellis Pharmaceuticals
Yungjin Pharm
Alpex Pharma
Bridge BioResearch
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Bupropion and Naltrexone
Orlistat
Lorcaserin
Phentermine and Topiramate
Liraglutide
Market Segment by Applications, can be divided into
Hospital Pharmacies
Retail Pharmacies
E-Commerce
There are 15 Chapters to deeply display the global Anti-Obesity Prescription market.
Chapter 1, to describe Anti-Obesity Prescription Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Anti-Obesity Prescription, with sales, revenue, and price of Anti-Obesity Prescription, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Anti-Obesity Prescription, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Anti-Obesity Prescription market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Anti-Obesity Prescription sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Anti-Obesity Prescription Introduction
1.2 Market Analysis by Type
1.2.1 Bupropion and Naltrexone
1.2.2 Orlistat
1.2.3 Lorcaserin
1.2.4 Phentermine and Topiramate
1.2.5 Liraglutide
1.3 Market Analysis by Applications
1.3.1 Hospital Pharmacies
1.3.2 Retail Pharmacies
1.3.3 E-Commerce
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Zydus Cadila
2.1.1 Business Overview
2.1.2 Anti-Obesity Prescription Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Zydus Cadila Anti-Obesity Prescription Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Akrimax Pharmaceuticals
2.2.1 Business Overview
2.2.2 Anti-Obesity Prescription Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Akrimax Pharmaceuticals Anti-Obesity Prescription Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Zealand Pharma
2.3.1 Business Overview
2.3.2 Anti-Obesity Prescription Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Zealand Pharma Anti-Obesity Prescription Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Arrowhead Research
2.4.1 Business Overview
2.4.2 Anti-Obesity Prescription Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Arrowhead Research Anti-Obesity Prescription Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Arena Pharmaceuticals
2.5.1 Business Overview
2.5.2 Anti-Obesity Prescription Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Arena Pharmaceuticals Anti-Obesity Prescription Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Compellis Pharmaceuticals
2.6.1 Business Overview
2.6.2 Anti-Obesity Prescription Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Compellis Pharmaceuticals Anti-Obesity Prescription Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Yungjin Pharm
2.7.1 Business Overview
2.7.2 Anti-Obesity Prescription Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Yungjin Pharm Anti-Obesity Prescription Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Alpex Pharma
2.8.1 Business Overview
2.8.2 Anti-Obesity Prescription Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Alpex Pharma Anti-Obesity Prescription Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Bridge BioResearch
2.9.1 Business Overview
2.9.2 Anti-Obesity Prescription Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Bridge BioResearch Anti-Obesity Prescription Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Anti-Obesity Prescription Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Anti-Obesity Prescription Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Anti-Obesity Prescription Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Anti-Obesity Prescription Manufacturer Market Share in 2017
3.3.2 Top 6 Anti-Obesity Prescription Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Anti-Obesity Prescription Market Analysis by Regions
4.1 Global Anti-Obesity Prescription Sales, Revenue and Market Share by Regions
4.1.1 Global Anti-Obesity Prescription Sales and Market Share by Regions (2013-2018)
4.1.2 Global Anti-Obesity Prescription Revenue and Market Share by Regions (2013-2018)
4.2 North America Anti-Obesity Prescription Sales and Growth Rate (2013-2018)
4.3 Europe Anti-Obesity Prescription Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Anti-Obesity Prescription Sales and Growth Rate (2013-2018)
4.5 South America Anti-Obesity Prescription Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Anti-Obesity Prescription Sales and Growth Rate (2013-2018)
5 North America Anti-Obesity Prescription by Countries
5.1 North America Anti-Obesity Prescription Sales, Revenue and Market Share by Countries
5.1.1 North America Anti-Obesity Prescription Sales and Market Share by Countries (2013-2018)
5.1.2 North America Anti-Obesity Prescription Revenue and Market Share by Countries (2013-2018)
5.2 United States Anti-Obesity Prescription Sales and Growth Rate (2013-2018)
5.3 Canada Anti-Obesity Prescription Sales and Growth Rate (2013-2018)
5.4 Mexico Anti-Obesity Prescription Sales and Growth Rate (2013-2018)
6 Europe Anti-Obesity Prescription by Countries
6.1 Europe Anti-Obesity Prescription Sales, Revenue and Market Share by Countries
6.1.1 Europe Anti-Obesity Prescription Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Anti-Obesity Prescription Revenue and Market Share by Countries (2013-2018)
6.2 Germany Anti-Obesity Prescription Sales and Growth Rate (2013-2018)
6.3 UK Anti-Obesity Prescription Sales and Growth Rate (2013-2018)
6.4 France Anti-Obesity Prescription Sales and Growth Rate (2013-2018)
6.5 Russia Anti-Obesity Prescription Sales and Growth Rate (2013-2018)
6.6 Italy Anti-Obesity Prescription Sales and Growth Rate (2013-2018)
7 Asia-Pacific Anti-Obesity Prescription by Countries
7.1 Asia-Pacific Anti-Obesity Prescription Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Anti-Obesity Prescription Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Anti-Obesity Prescription Revenue and Market Share by Countries (2013-2018)
7.2 China Anti-Obesity Prescription Sales and Growth Rate (2013-2018)
7.3 Japan Anti-Obesity Prescription Sales and Growth Rate (2013-2018)
7.4 Korea Anti-Obesity Prescription Sales and Growth Rate (2013-2018)
7.5 India Anti-Obesity Prescription Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Anti-Obesity Prescription Sales and Growth Rate (2013-2018)
8 South America Anti-Obesity Prescription by Countries
8.1 South America Anti-Obesity Prescription Sales, Revenue and Market Share by Countries
8.1.1 South America Anti-Obesity Prescription Sales and Market Share by Countries (2013-2018)
8.1.2 South America Anti-Obesity Prescription Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Anti-Obesity Prescription Sales and Growth Rate (2013-2018)
8.3 Argentina Anti-Obesity Prescription Sales and Growth Rate (2013-2018)
8.4 Colombia Anti-Obesity Prescription Sales and Growth Rate (2013-2018)
9 Middle East and Africa Anti-Obesity Prescription by Countries
9.1 Middle East and Africa Anti-Obesity Prescription Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Anti-Obesity Prescription Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Anti-Obesity Prescription Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Anti-Obesity Prescription Sales and Growth Rate (2013-2018)
9.3 UAE Anti-Obesity Prescription Sales and Growth Rate (2013-2018)
9.4 Egypt Anti-Obesity Prescription Sales and Growth Rate (2013-2018)
9.5 Nigeria Anti-Obesity Prescription Sales and Growth Rate (2013-2018)
9.6 South Africa Anti-Obesity Prescription Sales and Growth Rate (2013-2018)
10 Global Anti-Obesity Prescription Market Segment by Type
10.1 Global Anti-Obesity Prescription Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Anti-Obesity Prescription Sales and Market Share by Type (2013-2018)
10.1.2 Global Anti-Obesity Prescription Revenue and Market Share by Type (2013-2018)
10.2 Bupropion and Naltrexone Sales Growth and Price
10.2.1 Global Bupropion and Naltrexone Sales Growth (2013-2018)
10.2.2 Global Bupropion and Naltrexone Price (2013-2018)
10.3 Orlistat Sales Growth and Price
10.3.1 Global Orlistat Sales Growth (2013-2018)
10.3.2 Global Orlistat Price (2013-2018)
10.4 Lorcaserin Sales Growth and Price
10.4.1 Global Lorcaserin Sales Growth (2013-2018)
10.4.2 Global Lorcaserin Price (2013-2018)
10.5 Phentermine and Topiramate Sales Growth and Price
10.5.1 Global Phentermine and Topiramate Sales Growth (2013-2018)
10.5.2 Global Phentermine and Topiramate Price (2013-2018)
10.6 Liraglutide Sales Growth and Price
10.6.1 Global Liraglutide Sales Growth (2013-2018)
10.6.2 Global Liraglutide Price (2013-2018)
11 Global Anti-Obesity Prescription Market Segment by Application
11.1 Global Anti-Obesity Prescription Sales Market Share by Application (2013-2018)
11.2 Hospital Pharmacies Sales Growth (2013-2018)
11.3 Retail Pharmacies Sales Growth (2013-2018)
11.4 E-Commerce Sales Growth (2013-2018)
12 Anti-Obesity Prescription Market Forecast (2018-2023)
12.1 Global Anti-Obesity Prescription Sales, Revenue and Growth Rate (2018-2023)
12.2 Anti-Obesity Prescription Market Forecast by Regions (2018-2023)
12.2.1 North America Anti-Obesity Prescription Market Forecast (2018-2023)
12.2.2 Europe Anti-Obesity Prescription Market Forecast (2018-2023)
12.2.3 Asia-Pacific Anti-Obesity Prescription Market Forecast (2018-2023)
12.2.4 South America Anti-Obesity Prescription Market Forecast (2018-2023)
12.2.5 Middle East and Africa Anti-Obesity Prescription Market Forecast (2018-2023)
12.3 Anti-Obesity Prescription Market Forecast by Type (2018-2023)
12.3.1 Global Anti-Obesity Prescription Sales Forecast by Type (2018-2023)
12.3.2 Global Anti-Obesity Prescription Market Share Forecast by Type (2018-2023)
12.4 Anti-Obesity Prescription Market Forecast by Application (2018-2023)
12.4.1 Global Anti-Obesity Prescription Sales Forecast by Application (2018-2023)
12.4.2 Global Anti-Obesity Prescription Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Anti-Obesity Prescription Picture
Table Product Specifications of Anti-Obesity Prescription
Figure Global Sales Market Share of Anti-Obesity Prescription by Types in
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
